Treats operable node-positive BC Non-small Cell Lung Cancer (NSCLC). Sold as Taxotere, Docetaxel, Docefrez, Docivyx, Beizray. Every FDA application for this active ingredient: 11 branded and 20 generic.
As of Nov 13, 2026, FDA lists 31 applications for Docetaxel (sold as Taxotere, Docetaxel, Docefrez and others), first approved May 14, 1996, with 11 new uses approved and 0 published complete response letters.
| DOCIVYX | Part B | $45.0M | New | 1,849 |
| Docetaxel | Part B | $1.8M | -47% | 7,421 |
| Docetaxel | Part D | $1.4M | +11% | 838 |
| BEIZRAY-ALBUMIN | Part B | $98K | New | 12 |
| Docivyx | Part D | $85K | New | 0 |
| PDS Versus NACT-IDS in AI-Selected Advanced Epithelial Ovarian CancerEpithelial Ovarian Cancer, Fallopian Tube Cancers · Shanghai Gynecologic Oncology Group | Phase 2 / Phase 3 | Not yet recruiting | Nov 12, 2026 |
| Predicting Benefit From Anthracycline-Free Adjuvant Chemotherapy in High-Risk HER2-Negative Breast CancerBreast Neoplasms, HER2-negative Breast Cancer · Peking Union Medical College Hospital | — | Active, not recruiting | Nov 9, 2026 |
| Tislelizumab Combined With Tofacitinib and Docetaxel for NSCLC After Failure of First-Line ImmunotherapyPatients With Locally Advanced or Metastatic NSCLC Who Have Failed First-line Immunotherapy · Anhui Provincial Hospital | Phase 2 | Recruiting | Nov 9, 2026 |
| MK-2870-U01 Substudy 1: A Clinical Trial of Sacituzumab Tirumotecan to Treat Prostate Cancer (MK-2870-01A)Metastatic Castration-resistant Prostate Cancer · Merck Sharp & Dohme LLC | Phase 1 / Phase 2 | Not yet recruiting | Nov 2, 2026 |
| Deutenzalutamide and Hormone Therapy Before and After Surgery With Docetaxel Before Surgery for High-Risk Localized or Locally Advanced Prostate CancerProstate Cancer (Adenocarcinoma) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 | Not yet recruiting | Oct 30, 2026 |
| Serplulimab, DOS and Lenvatinib Combine With PIPAC in the Oligometastatic Peritoneal Metastasis of Gastric/Gastroesophageal Junction AdenocarcinomaGastric/Gastroesophageal Junction Adenocarcinoma, Oligometastatic Peritoneal Metastasis · Fujian Cancer Hospital | Phase 2 | Not yet recruiting | Oct 29, 2026 |
| A Prospective, Phase II, Exploratory Study Protocol of a Chemotherapy Sensitivity-based Culmerciclib Combination Regimen in Neoadjuvant Therapy for HR+/HER2- Breast Cancer.Breast Cancer · The First Affiliated Hospital with Nanjing Medical University | Phase 2 | Recruiting | Oct 28, 2026 |
| Propranolol Hydrochloride Combined With Toripalimab and Platinum-based Chemotherapy in Resectable Non-Small Cell Lung CancerResectable Non-Small-Cell Lung Cancer · Second Xiangya Hospital of Central South University | Phase 1 | Recruiting | Oct 21, 2026 |
| May 14, 1996 | TaxotereNDA 20449 · New molecular entity | Sanofi Aventis US | 51 | Marketed |
| Mar 8, 2011 | DocetaxelNDA 22234 · New formulation or manufacturer | Hospira Inc | 12 | Marketed |
| May 3, 2011 | Docefrez, DocetaxelNDA 22534 · New formulation or manufacturer | Sun Pharm | 10 | Discontinued |
| Jun 8, 2011 | DocetaxelNDA 201195 · New formulation or manufacturer | Accord Hlthcare | 9 | Marketed |
| Jun 29, 2011 | DocetaxelNDA 201525 · New formulation or manufacturer | Sandoz | 13 | Marketed |
| Jan 11, 2012 | DocetaxelNDA 22312 · New formulation or manufacturer | Apotex Inc | 0 | Discontinued |
| Apr 12, 2013 | DocetaxelNDA 203551 · New formulation or manufacturer | Actavis | 8 | Marketed |
| Mar 13, 2014 | DocetaxelNDA 202356 · New formulation or manufacturer | Pfizer Labs | 3 | Discontinued |
| Nov 5, 2014 | DocetaxelANDA 204193 | Dr Reddys | 6 | Marketed |
| Sep 16, 2015 | DocetaxelANDA 203877 | Teva Pharms USA | 2 | Discontinued |
| Dec 22, 2015 | DocetaxelNDA 205934 · New formulation or manufacturer | Shilpa | 3 | Marketed |
| Jan 20, 2017 | DocetaxelANDA 206177 | Dfb Oncology Ltd | 0 | Discontinued |
| Feb 15, 2017 | DocetaxelANDA 203170 | Hengrui Pharma | 4 | Discontinued |
| Aug 9, 2017 | DocetaxelANDA 207252 | Hengrui Pharma | 6 | Marketed |
| Aug 31, 2017 | DocetaxelANDA 207563 | Ingenus Pharms LLC | 4 | Discontinued |
| Jan 19, 2018 | DocetaxelANDA 209640 | Amneal | 5 | Marketed |
| Apr 30, 2018 | DocetaxelANDA 208859 | Mylan Labs Ltd | 4 | Marketed |
| Jul 2, 2018 | DocetaxelANDA 210072 | Mylan Labs Ltd | 4 | Marketed |
| Jul 6, 2018 | DocetaxelANDA 210848 | Mylan Labs Ltd | 4 | Marketed |
| Aug 24, 2018 | DocetaxelANDA 209634 | Meitheal | 3 | Marketed |
| Apr 1, 2019 | DocetaxelANDA 208137 | Mylan Labs Ltd | 1 | Marketed |
| May 16, 2019 | DocetaxelANDA 210327 | Adaptis | 4 | Marketed |
| Jan 14, 2021 | DocetaxelANDA 204490 | Hikma | 0 | Marketed |
| Jun 25, 2021 | DocetaxelANDA 214575 | Eugia Pharma | 1 | Discontinued |
| Jul 1, 2021 | DocetaxelANDA 213510 | Gland | 1 | Marketed |
| Nov 22, 2022 | Docivyx, DocetaxelNDA 215813 · New formulation or manufacturer | Avyxa Holdings | 3 | Marketed |
| Feb 28, 2023 | DocetaxelANDA 215744 | Alembic | 1 | Marketed |
| May 11, 2023 | DocetaxelANDA 203892 | Pharmobedient | 0 | Discontinued |
| Feb 28, 2024 | DocetaxelANDA 216677 | Heritage | 0 | Marketed |
| Oct 23, 2024 | BeizrayNDA 218711 · New formulation or manufacturer | Zhuhai | 1 | Marketed |
| May 13, 2025 | DocetaxelANDA 213768 | Guangdong Sunho | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Sanofi Aventis US
Accord Hlthcare
Sandoz
Mylan Labs Ltd
Hikma
Eugia Pharma
Alembic